iTeos Therapeutics (NASDAQ:ITOS) Earns Outperform Rating from Wedbush

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a note issued to investors on Friday,RTT News reports. They currently have a $25.00 price target on the stock. Wedbush’s price objective would indicate a potential upside of 222.16% from the company’s previous close.

A number of other equities analysts have also recently commented on the company. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of iTeos Therapeutics in a report on Friday, December 13th. Wells Fargo & Company lowered their target price on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th.

iTeos Therapeutics Stock Down 0.6 %

ITOS opened at $7.76 on Friday. iTeos Therapeutics has a twelve month low of $7.09 and a twelve month high of $18.75. The stock has a market capitalization of $283.50 million, a price-to-earnings ratio of -2.46 and a beta of 1.39. The company has a 50-day simple moving average of $8.13 and a 200 day simple moving average of $11.76.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.18) by $0.13. Sell-side analysts anticipate that iTeos Therapeutics will post -3.46 EPS for the current fiscal year.

Insider Activity

In other news, CFO Matthew Gall acquired 5,000 shares of the stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the purchase, the chief financial officer now directly owns 65,429 shares of the company’s stock, valued at $505,766.17. This represents a 8.27 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 12.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On iTeos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ITOS. The Manufacturers Life Insurance Company raised its stake in shares of iTeos Therapeutics by 6.6% during the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after acquiring an additional 690 shares during the last quarter. Creative Planning increased its holdings in iTeos Therapeutics by 6.5% in the third quarter. Creative Planning now owns 19,636 shares of the company’s stock valued at $200,000 after purchasing an additional 1,196 shares during the period. nVerses Capital LLC raised its position in iTeos Therapeutics by 212.5% during the 3rd quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock worth $26,000 after purchasing an additional 1,700 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in iTeos Therapeutics by 60.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after buying an additional 2,646 shares during the period. Finally, Point72 DIFC Ltd bought a new stake in shares of iTeos Therapeutics in the 3rd quarter valued at about $31,000. 97.16% of the stock is owned by institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.